Trial · NCT01147822
Adverse events880
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 880
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pazopanib 800 mg | 11 | 186 | |
| other | Anaemia | Blood and lymphatic system disorders | Sunitinib 50 mg | 50 | 177 | |
| other | Anaemia | Blood and lymphatic system disorders | Pazopanib 800 mg (Post-Treatment) | 0 | ||
| other | Anaemia | Blood and lymphatic system disorders | Sunitinib 50 mg (Post-Treatment) | 0 | ||
| other | Leukopenia | Blood and lymphatic system disorders | Pazopanib 800 mg | 40 | 186 | |
| other | Leukopenia | Blood and lymphatic system disorders | Sunitinib 50 mg | 61 | 177 | |
| other | Leukopenia | Blood and lymphatic system disorders | Pazopanib 800 mg (Post-Treatment) | 0 | ||
| other | Leukopenia | Blood and lymphatic system disorders | Sunitinib 50 mg (Post-Treatment) | 0 | ||
| other | Lymphopenia | Blood and lymphatic system disorders | Pazopanib 800 mg | 3 | 186 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Sunitinib 50 mg | 11 | 177 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Pazopanib 800 mg (Post-Treatment) | 0 | ||
| other | Lymphopenia | Blood and lymphatic system disorders | Sunitinib 50 mg (Post-Treatment) | 0 | ||
| other | Neutropenia | Blood and lymphatic system disorders | Pazopanib 800 mg | 43 | 186 | |
| other | Neutropenia | Blood and lymphatic system disorders | Sunitinib 50 mg | 77 | 177 | |
| other | Neutropenia | Blood and lymphatic system disorders | Pazopanib 800 mg (Post-Treatment) | 0 | ||
| other | Neutropenia | Blood and lymphatic system disorders | Sunitinib 50 mg (Post-Treatment) | 0 | ||
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pazopanib 800 mg | 29 | 186 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Sunitinib 50 mg | 80 | 177 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pazopanib 800 mg (Post-Treatment) | 0 | ||
| other | Thrombocytopenia | Blood and lymphatic system disorders | Sunitinib 50 mg (Post-Treatment) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01147822/events